CR20210545A - Formas sólidas de un inhibidor de glyt1 - Google Patents

Formas sólidas de un inhibidor de glyt1

Info

Publication number
CR20210545A
CR20210545A CR20210545A CR20210545A CR20210545A CR 20210545 A CR20210545 A CR 20210545A CR 20210545 A CR20210545 A CR 20210545A CR 20210545 A CR20210545 A CR 20210545A CR 20210545 A CR20210545 A CR 20210545A
Authority
CR
Costa Rica
Prior art keywords
solid forms
inhibitor
glyt1 inhibitor
glyt1
glycine transporter
Prior art date
Application number
CR20210545A
Other languages
English (en)
Inventor
Joe Ju Gao
Peter Sieger
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20210545A publication Critical patent/CR20210545A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). La invención también se refiere a métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1.
CR20210545A 2019-05-01 2020-04-30 Formas sólidas de un inhibidor de glyt1 CR20210545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Publications (1)

Publication Number Publication Date
CR20210545A true CR20210545A (es) 2021-12-23

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210545A CR20210545A (es) 2019-05-01 2020-04-30 Formas sólidas de un inhibidor de glyt1

Country Status (23)

Country Link
US (2) US11447474B2 (es)
EP (1) EP3962911A1 (es)
JP (2) JP7513349B2 (es)
KR (1) KR20220004174A (es)
CN (1) CN113784966B (es)
AR (1) AR118839A1 (es)
AU (1) AU2020266566A1 (es)
BR (1) BR112021020883A2 (es)
CA (1) CA3138288A1 (es)
CL (1) CL2021002837A1 (es)
CO (1) CO2021014260A2 (es)
CR (1) CR20210545A (es)
DO (1) DOP2021000224A (es)
EA (1) EA202192925A1 (es)
EC (1) ECSP21082195A (es)
IL (1) IL287630A (es)
JO (1) JOP20210295A1 (es)
MA (1) MA55801A (es)
MX (1) MX2021013341A (es)
PE (1) PE20212263A1 (es)
SG (1) SG11202111972YA (es)
TW (1) TW202106680A (es)
WO (1) WO2020223419A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
AU2021205510A1 (en) 2020-01-09 2022-07-21 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
WO2022034146A1 (en) * 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
BR112023004774A2 (pt) 2020-10-13 2023-04-25 Boehringer Ingelheim Int Processo de retrabalho

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
KR20060095865A (ko) * 2003-10-14 2006-09-04 화이자 프로덕츠 인크. 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
CA2745690A1 (en) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
CN102271677A (zh) * 2008-12-29 2011-12-07 凡德贝尔大学 3.1.0双环G1yT1抑制剂及其制备和使用方法
US9012489B2 (en) 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US10919891B2 (en) 2017-04-27 2021-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
JP2024100792A (ja) 2024-07-26
CO2021014260A2 (es) 2021-10-29
DOP2021000224A (es) 2021-12-15
JOP20210295A1 (ar) 2023-01-30
WO2020223419A1 (en) 2020-11-05
SG11202111972YA (en) 2021-11-29
US11447474B2 (en) 2022-09-20
US20220332710A1 (en) 2022-10-20
JP7513349B2 (ja) 2024-07-09
CA3138288A1 (en) 2020-11-05
AR118839A1 (es) 2021-11-03
CN113784966A (zh) 2021-12-10
US20200347041A1 (en) 2020-11-05
JP2022530630A (ja) 2022-06-30
CL2021002837A1 (es) 2022-07-29
CN113784966B (zh) 2024-07-19
MX2021013341A (es) 2021-11-17
IL287630A (en) 2021-12-01
KR20220004174A (ko) 2022-01-11
EA202192925A1 (ru) 2022-03-23
BR112021020883A2 (pt) 2022-04-19
PE20212263A1 (es) 2021-11-29
ECSP21082195A (es) 2021-12-30
EP3962911A1 (en) 2022-03-09
AU2020266566A1 (en) 2021-11-11
TW202106680A (zh) 2021-02-16
MA55801A (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
JOP20210295A1 (ar) أشكال صلبة لمثبط GlyT1
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
GEP20217318B (en) Pyrazole magl inhibitors
PH12019550241A1 (en) Mic-1 compounds and uses thereof
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2021007460A (es) Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
AU2017247612A9 (en) Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety
PH12020551618A1 (en) Erenumab compositions and uses thereof
WO2017106798A3 (en) Compositions and methods for treating gluten intolerance and disorders arising therefrom
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
PH12017501918A1 (en) Multi-peptide composition
MX2018003289A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO.